Welcome to our dedicated page for Tff Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (TFFP) has been described in its public communications as a clinical-stage biopharmaceutical company built around its proprietary Thin Film Freezing (TFF) technology platform. Over time, the company has issued news covering its inhaled dry powder product candidates, collaborations with academic and government partners, and later, significant corporate developments related to winding down operations and delisting from Nasdaq.
Earlier news from TFF Pharmaceuticals has focused on the progress of its TFF-based pipeline. This includes updates on tacrolimus inhalation powder (TFF TAC) for the prevention of lung transplant rejection, where the company has reported Phase 2 clinical data on safety, pharmacokinetics, biomarker outcomes, and patient enrollment. Additional releases have highlighted preclinical data for TFF-formulated influenza vaccine candidates and work on inhaled or intranasal dry powder formulations designed to address respiratory viral infections, including influenza and COVID, often in collaboration with institutions such as Emory University and Cleveland Clinic and with support from U.S. government agencies.
News items have also described the broader capabilities of the Thin Film Freezing platform, including its application to vaccines, small and large molecules, and biologics, and its potential to create temperature-stable dry powders suitable for inhalation or topical delivery. Corporate updates have included financial results, regulatory interactions with the U.S. Food and Drug Administration regarding the TFF TAC program, and the engagement of advisors to explore partnership and licensing opportunities.
More recent announcements mark a shift in focus, with TFF Pharmaceuticals disclosing the termination of its employees, a decision to wind down operations, and plans for liquidation and dissolution. The company has also announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market, stating that this step is being taken in connection with the planned liquidation. This news page provides a record of both the scientific and clinical developments associated with the TFF platform and the subsequent corporate decisions affecting the company’s trading status and future.
NeuroRx and TFF Pharmaceuticals announced a feasibility and material transfer agreement to develop a long-term stable inhalable formulation of ZYESAMI™. This agreement involves testing ZYESAMI™, a synthetic peptide, aimed at treating COVID-19 by potentially improving lung function. The collaboration leverages TFF's thin film freezing technology to enhance aerosol delivery of the drug to patients. ZYESAMI™ has shown significant results in reducing hospital discharge times for COVID-19 patients, emphasizing its therapeutic potential for respiratory distress.
NeuroRx and TFF Pharmaceuticals (NASDAQ: TFFP) have signed a Feasibility Agreement, enabling the transfer of ZYESAMI™ materials to TFF for formulation work. This aims to develop a stable dry powder version of ZYESAMI™, enhancing aerosol delivery to the lungs. ZYESAMI™ is a synthetic peptide that aids in treating lung conditions linked to COVID-19 by potentially increasing surfactant production. The collaboration seeks to broaden its therapeutic applications, particularly for patients with varying severity of COVID-19 symptoms.
GreenLight Biosciences and TFF Pharmaceuticals have partnered to explore feasibility studies for developing a shelf-stable powder form of a messenger RNA COVID-19 vaccine. This collaboration aims to simplify vaccine distribution by eliminating the need for extreme cold storage, which complicates logistics and increases costs. The partnership could lead to vaccines that can be transported at higher temperatures and reconstituted before administration. If successful, this initiative may significantly enhance global vaccine accessibility and response to the pandemic.
GreenLight Biosciences and TFF Pharmaceuticals have partnered to explore a feasibility study for a shelf-stable dry powder form of a COVID-19 mRNA vaccine. This collaboration aims to address challenges associated with current cold chain requirements for vaccine distribution, which necessitate temperatures as low as -80°C. If successful, the new formulation could simplify vaccine delivery worldwide, especially in regions with limited cold chain infrastructure. TFF Pharmaceuticals will test the reconstitutability and viability of the vaccine candidate, which may lead to innovative, non-needle administration methods.
TFF Pharmaceuticals (NASDAQ: TFFP) will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, and the 33rd Annual ROTH Conference on March 15-17, 2021. Glenn Mattes, President & CEO, will deliver pre-recorded presentations. Dr. Dale Christensen will join a panel discussion at ROTH on March 15th at 12 PM ET, discussing therapeutics against SARS-CoV-2. Recordings will be available for registered attendees on the TFF Pharmaceuticals website. TFF's technology enhances drug solubility for effective inhalation.
TFF Pharmaceuticals (NASDAQ: TFFP) has reported progress in clinical trials for its Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Phase 1 trial for Voriconazole showed no significant adverse events, with blood levels exceeding expectations, marking it as a promising treatment for invasive pulmonary aspergillosis (IPA). TFF has selected an 80 mg dose for an upcoming pivotal trial. The Single Ascending Dose phase for Tacrolimus has also been completed, achieving therapeutic levels without adverse effects, indicating potential applications beyond lung transplants.
TFF Pharmaceuticals (NASDAQ: TFFP) will announce its financial results for Q4 and full-year 2020 on March 10, 2021, after U.S. market close. A conference call is scheduled at 4:30 PM ET to discuss these results and recent developments, followed by a Q&A session. The TFF platform enhances the solubility and absorption of poorly water-soluble drugs, particularly for inhalation therapy, and is supported by 42 patents. The company is advancing its lead candidates, Voriconazole and Tacrolimus Inhalation Powders, in collaboration with pharmaceutical partners.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) announced positive preclinical in vitro efficacy data for TFF formulated biodefense countermeasures. Their collaboration, established in April 2020, focused on developing needle-free, temperature-insensitive inhaled treatments. Results showed preserved efficacy for a monoclonal antibody against Ebolavirus and a vaccine candidate against Venezuelan equine encephalitis. Future steps include in vivo testing. This advancement highlights the potential of TFF's technology to enhance biodefense measures for military personnel.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a biopharmaceutical firm specializing in innovative drug products, will participate in the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. CEO Glenn Mattes will present a pre-recorded session available on-demand for 30 days to registered attendees. TFF Pharmaceuticals utilizes its patented Thin Film Freezing (TFF) technology to enhance drug solubility and absorption, focusing on inhalation delivery to the deep lung, with potential drug deposition as high as 75%. The company aims to expand its pipeline through collaborations.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) has been invited to present at H.C. Wainwright’s BioConnect 2021 Conference, taking place virtually from January 11-14, 2021. CEO Glenn Mattes will deliver a pre-recorded presentation available on-demand for one week starting January 11 at 6:00 AM Eastern time. The company will also engage with investors at the Biotech Showcase and participate in meetings through BIO’s One-on-One Partnering System throughout the event. TFF Pharmaceuticals focuses on its patented Thin Film Freezing technology, aimed at enhancing drug solubility and absorption.